iTeos Therapeutics, Inc.

iTeos reported third-quarter 2021 revenue of $104.3 million, versus no revenue in the third quarter of 2020, with nearly all of it from recognition of a portion of the $625 million GSK upfront payment. Research and development expense was $16.1 million, up from $8.7 million a year ago, and general and administrative expense was $8.8 million, up from $4.8 million. Net income attributable to common shareholders was $69.6 million, or $1.98 per basic share and $1.86 per diluted share, versus a net loss of $11.6 million, or $(0.48) per basic and diluted share, in Q3 2020. Cash and cash equivalents were $899.8 million at September 30, 2021, versus $340.0 million a year earlier; management said this cash balance should fund operating expenses and capital expenditures into 2026. No next-quarter or full-year revenue/EPS guidance was provided on the call.

Michel Detheux framed the quarter around iTeos’ tumor-microenvironment strategy and the company’s ability to turn biology into differentiated clinical programs. He emphasized that the GSK partnership validates TIGIT as an important immuno-oncology target and gives iTeos strategic flexibility, including co-commercialization rights in the U.S. His tone was upbeat and promotional, but centered on execution and building a broader pipeline beyond the lead assets.

Matthew Gall focused on the balance sheet and the accounting impact of the GSK deal. He said cash and cash equivalents were $899.8 million at September 30, 2021, up from $340.0 million a year earlier, and that the company expects this to fund operating expenses and capital expenditures into 2026. He also tied the $104.3 million of quarterly revenue almost entirely to upfront-payment recognition and explained that higher R&D and G&A were driven by more clinical activity, pipeline expansion, hiring, and public-company costs.

Analysts pressed on whether the inupadenant combination data were strong enough to justify further development, and management said the selected doses had acceptable safety, expected PK, and early efficacy signals. Management also clarified it is not advancing inupadenant plus pembrolizumab in prostate cancer, saying there are better development options. Questions on EOS-448 focused on why a pembrolizumab combo is being run before dostarlimab; management said the pembro study is mainly to move faster and generate dose-setting data, while also evaluating different anti-PD-1 partners. Analysts also asked about biomarker stratification, and management said it is incorporating an adenosine/A2A-related assay into future studies, including melanoma and planned randomized work next year.